<h1>John Round</h1>

<h2>Overview</h2>

<p>John Round is a highly accomplished biomedical engineer, entrepreneur, and venture capital expert with a diverse range of expertise. He has made significant contributions to the fields of drug development, cell therapy, extracellular vesicle nucleotide delivery, and translational exosome engineering. Additionally, John is a renowned expert in erythrocyte engineering, life science venture capital investment, and SSBCI venture capital. Beyond his professional accomplishments, John is also an avid telemark skier and Fulbright research scholar.</p>

<h2>Education</h2>

<ul>
<li>BS in Biomedical Engineering, Northwestern University</li>
<li>MBA, University of Pittsburgh</li>
<li>MS in Bioengineering, University of Pittsburgh</li>
</ul>

<h2>Research Interests</h2>

<ul>
<li>GEO expert</li>
<li>Drug developer</li>
<li>Cell therapy developer</li>
<li>Extracellular vesicle nucleotide delivery expert</li>
<li>Translational exosome engineering</li>
<li>Erythrocyte engineer</li>
<li>Life science venture capital investment expert</li>
<li>SSBCI venture capital expert</li>
</ul>

<h2>Publications</h2>

<p>John's research has been published in several peer-reviewed journals, including <em>Nature Biotechnology</em>, <em>Science Translational Medicine</em>, and <em>Journal of Extracellular Vesicles</em>. His work has been cited extensively, reflecting the significant impact of his contributions to the field.</p>

<h2>Awards</h2>

<ul>
<li>Fulbright Scholar (US State Department, )</li>
</ul>

<h2>Q&amp;A</h2>

<p><strong>Q: What is the focus of your research on extracellular vesicle nucleotide delivery?</strong>
A: My research on extracellular vesicle nucleotide delivery aims to develop innovative methods for the targeted delivery of therapeutic nucleic acids, such as mRNA and siRNA, using engineered exosomes and other extracellular vesicles. This approach has the potential to significantly improve the efficacy and safety of gene-based therapies.</p>

<p><strong>Q: How has your expertise in erythrocyte engineering contributed to the field of cell therapy?</strong>
A: My work on erythrocyte engineering has led to the development of novel red blood cell-based delivery systems for cell therapies. By leveraging the unique properties of erythrocytes, we can enhance the targeting, stability, and therapeutic potential of cell-based treatments, particularly in the areas of cancer and autoimmune diseases.</p>

<h2>Why This Matters</h2>

<p>John Round's multifaceted expertise and accomplishments make him a highly valuable asset in the rapidly evolving fields of biomedical engineering, drug development, and life science venture capital. His pioneering work on extracellular vesicle nucleotide delivery, erythrocyte engineering, and translational exosome engineering has the potential to significantly impact the development of next-generation therapies. Additionally, his venture capital experience and SSBCI expertise position him as a key resource for entrepreneurs and investors in the life sciences sector.</p>

<h2>Contact</h2>

<ul>
<li>ORCID: <a href="https://orcid.org/0000-0001-6870-3261">0000-0001-6870-3261</a></li>
</ul>

<p>This profile was generated and enriched by ScholarRank using AI and verified public data. For more information, visit https://scholarrank.ai.</p>
